Communiqués de presse MaaT Pharma selected in the Big Booster TOP 10 MaaT Pharma, which develops the first treatment using an autologous intestinal microbiota transplant is now…MaaT Pharmafévrier 16, 2016
Communiqués de presse MaaT Pharma accelerates its development with the closing of EUR 1 M in second fundraising Important step in developing microbiome therapy for severe intestinal Dysbiosis.MaaT Pharmajuillet 24, 2015
Communiqués de presse MaaT Pharma raises EUR 1 M (USD 1.25M) in First Investment Round Financing to develop microbiome therapy for severe intestinal dysbiosisMaaT Pharmajanvier 12, 2015
